BioNTech has abruptly terminated a Phase 2 trial of its experimental personalized mRNA cancer “vaccine” after an independent safety board identified an alarming imbalance in overall survival between the treatment groups.
The trial, known as BNT122-01 (NCT04486378), enrolled …
